← Leaderboards
Stephen X Skapek
St. Jude Children'S Research Hospital
$24,951,237
Attributed
$53,484,730
Total exposure
12
Grants
9
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $8.4M · FY2005–25$10M$7.5M$5M$2.5M$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$53,484,730 · 12
By mechanism
U24$38,672,494 · 1
R01$6,029,934 · 2
RC2$2,862,111 · 1
U54$2,210,281 · 1
U10$1,792,024 · 1
T32$949,159 · 1
Top collaborators
- Mignon Lee-Cheun Loh8 shared
- Nilsa Del Carmen Ramirez8 shared
- Peter C Adamson5 shared
- Lin Xu4 shared
- Timothy J. Triche2 shared
Most similar at St. Jude Children'S Research Hospital
Same institution · by research overlap
- Mark Edward Hatley$4,899,188
- Janet Anne Houghton$8,199,871
- Xiang Chen$2,994,809
- Martine F Roussel$7,153,067
- Eric B Gibbs$67,446
Others in their field
Top investigators on “Malignant Neoplasms”
- David Heimbrook · Leidos Biomedical Research, Inc.$1,074,554,219
- Leonard Freedman · Leidos Biomedical Research, Inc.$527,106,485
- Ethan Dmitrovsky · Leidos Biomedical Research, Inc.$357,875,933
- Richard K. Wilson · Washington University$274,272,747
- Larry Arthur$223,443,122
- Lynn Briscoe · Leidos Biomedical Research, Inc.$186,892,879
Research focus
Malignant NeoplasmsBaseMolecularTumorChildCellsInsightClinical TrialsResearch PersonnelGenesLaboratoriesPathogenesisBiologyMalignant Childhood NeoplasmPlayGeneticDiagnosisPositioning AttributeResourcesFosteringProteinsSuccessTumor Suppressor GenesTumor Suppressor Proteins
Grant awards (50)
COG Biospecimen Bank to Support NCI NCTN (U24)$8,404,851
U24 · FY2025 · CA
COG Biospecimen Bank to Support NCI NCTN (U24)$6,232,880
U24 · FY2024 · CA
Nominating vulnerabilities in fusion oncoprotein-driven rhabdomyosarcoma$182,090
R21 · FY2024 · CA · contact PI
Nominating vulnerabilities in fusion oncoprotein-driven rhabdomyosarcoma$1
R21 · FY2024 · CA · contact PI
COG Biospecimen Bank to Support NCI NCTN (U24)$3,678,162
U24 · FY2023 · CA
COG Biobanking Support$2,900,934
U24 · FY2023 · CA
Nominating vulnerabilities in fusion oncoprotein-driven rhabdomyosarcoma$230,010
R21 · FY2023 · CA · contact PI
COG Biospecimen Bank to Support NCI NCTN (U24)$3,411,104
U24 · FY2022 · CA
COG Relapse Tumor- Supplement$1,794,931
U24 · FY2022 · CA
Development and Cancer Program$26,274
P30 · FY2022 · CA · contact PI
COG Biospecimen Bank to Support NCI NCTN (U24)$7,636,196
U24 · FY2021 · CA
Identifying neuroblastoma drivers and bringing them to the clinic$437,425
R21 · FY2021 · CA · contact PI
Development and Cancer Program$26,274
P30 · FY2021 · CA · contact PI
COG Biospecimen Bank to Support NCI NCTN (U24)$4,613,436
U24 · FY2020 · CA
Development and Cancer Scientific Program$35,011
P30 · FY2020 · CA · contact PI
ANTECEDANTS SEQUELAE OF CHILDHOOD ONSET DISEASE$31,642
K12 · FY2020 · HD · contact PI
Project 2: Targeted Therapies for Malignant Peripheral Nerve Sheath Tumors$409,015
U54 · FY2019 · CA · contact PI
Project 2: Targeted Therapies for Malignant Peripheral Nerve Sheath Tumors$439,640
U54 · FY2018 · CA · contact PI
Physician Scientist Oncology Training Program$286,741
T32 · FY2018 · CA · contact PI
COG NCTN Solid Malignancy Integrated Translational Science Center$192,024
U10 · FY2018 · CA
Project 2: Targeted Therapies for Malignant Peripheral Nerve Sheath Tumors$441,855
U54 · FY2017 · CA · contact PI
COG NCTN Solid Malignancy Integrated Translational Science Center$400,000
U10 · FY2017 · CA
Tgf Beta 2 controls p19Arf During Eye Development$397,500
R01 · FY2017 · EY · contact PI
Physician Scientist Oncology Training Program$245,302
T32 · FY2017 · CA · contact PI
Project 2: Targeted Therapies for Malignant Peripheral Nerve Sheath Tumors$434,302
U54 · FY2016 · CA · contact PI
COG NCTN Solid Malignancy Integrated Translational Science Center$400,000
U10 · FY2016 · CA
Tgf Beta 2 controls p19Arf During Eye Development$397,500
R01 · FY2016 · EY · contact PI
Physician Scientist Oncology Training Program$188,418
T32 · FY2016 · CA · contact PI
Project 2: Targeted Therapies for Malignant Peripheral Nerve Sheath Tumors$485,469
U54 · FY2015 · CA · contact PI
COG NCTN Solid Malignancy Integrated Translational Science Center$400,000
U10 · FY2015 · CA
Tgf Beta 2 controls p19Arf During Eye Development$389,550
R01 · FY2015 · EY · contact PI
Physician Scientist Oncology Training Program$228,698
T32 · FY2015 · CA · contact PI
COG NCTN Solid Malignancy Integrated Translational Science Center$400,000
U10 · FY2014 · CA
Tgf Beta 2 controls p19Arf During Eye Development$397,500
R01 · FY2014 · EY · contact PI
ARF Controls Vascular Regression During Eye Development$381,586
R01 · FY2012 · EY · contact PI
Tgf 2-2 controls p19Arf during eye development$342,630
R01 · FY2012 · EY · contact PI
ARF Controls Vascular Regression During Eye Development$369,600
R01 · FY2011 · EY · contact PI
Tgf 2-2 controls p19Arf during eye development$336,960
R01 · FY2011 · EY · contact PI
Translation of Predictive Cancer Biomarkers into Clinical Practice$1,308,910
RC2 · FY2010 · CA
ARF Controls Vascular Regression During Eye Development$381,150
R01 · FY2010 · EY · contact PI
Tgf 2-2 controls p19Arf during eye development$351,000
R01 · FY2010 · EY · contact PI
Translation of Predictive Cancer Biomarkers into Clinical Practice$1,553,201
RC2 · FY2009 · CA
ARF Controls Vascular Regression During Eye Development$385,000
R01 · FY2009 · EY · contact PI
ARF Controls Vascular Regression During Eye Development$385,000
R01 · FY2008 · EY · contact PI
ARF controls vascular regression during eye development$276,143
R01 · FY2007 · EY · contact PI
ARF controls vascular regression during eye development$15,165
R01 · FY2007 · EY · contact PI
ARF controls vascular regression during eye development$292,950
R01 · FY2006 · EY · contact PI
ARF controls vascular regression during eye development$300,000
R01 · FY2005 · EY
ARF controls vascular regression during eye development$300,000
R01 · FY2004 · EY
ARF controls vascular regression during eye development$330,700
R01 · FY2003 · EY